Clinical trials: Advanced Malignant Tumors
Advanced Solid Tumors
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
This is an extension study of ABT-806 for subjects with advanced solid tumors.
- Trial name
- NCT01406119
- Testing
- ABT-806
- Where
- 4 sites in United States, Australia
- Volunteers
- 14 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with Pembrolizumab Injection in Patients with…
- Trial name
- NCT05145907
- Testing
- TJ107 +Pembrolizumab
- Where
- 20 sites in China
- Volunteers
- 133 people
- Sponsor
- TJ Biopharma Co., Ltd.
Cancer, Multiple Indications
Multiple Ascending Dose (MDX1105-01)
Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.
- Trial name
- Anti-PDL1 (NCT00729664)
- Testing
- Anti-PDL-1 antibody
- Where
- 11 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
The purpose of this study is to determine if BMS-986310 administered in combination with nivolumab, will demonstrate adequate safety and tolerability, as well as a favorable risk/benefit profile, to support further clinical…
- Trial name
- NCT03661632
- Testing
- BMS-986310, Nivolumab
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 27 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer, Solid Tumors
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in…
- Conditions
- Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
- Trial name
- TroFuse-008 (NCT06049212)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Stage Solid Tumors
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
- Trial name
- NCT06255665
- Testing
- JNJ-79032421
- Where
- 3 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and…
- Trial name
- NCT02048709
- Testing
- GDC-0919
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.
Advanced or Metastatic Solid Tumors
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic solid tumors.
- Trial name
- NCT04843709
- Testing
- MRG004A
- Where
- 9 sites in United States, China
- Volunteers
- 39 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Advanced Tumors
A Study of AL58805 in Patients With Advanced Tumors
This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and…
- Trial name
- NCT07179081
- Testing
- AL58805
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Locally Advanced Unresectable Carcinoma
A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a multi-center, open-label, dose escalation and expansion, phase I study to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) characteristics, preliminary efficacy of SYHA1815 in…
- Trial name
- NCT05105464
- Testing
- SYHA1815
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Solid Tumor
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT07327632
- Testing
- IBI3026
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult…
- Conditions
- Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT07169734
- Testing
- ALE.P03
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 180 people
- Sponsor
- Alentis Therapeutics AG
Ovarian Cancer
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors.
- Trial name
- NCT07778498
- Testing
- TJ102
- Where
- 9 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Phrontline Biopharma
Advanced Solid Tumors
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
The primary objective of this study is to: Evaluate the safety and tolerability of AMG 305 in adult participants Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the…
- Trial name
- NCT05800964
- Testing
- AMG 305
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 37 people
- Sponsor
- Amgen
Tumor, Solid
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
- Trial name
- NCT04819373
- Testing
- BDB001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Eikon Therapeutics
Neoplasms
Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors.
- Trial name
- NCT00257881
- Testing
- CMD-193
- Where
- 2 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Merkel Cell Carcinoma, Basal Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer.
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Trial name
- ARTACUS (NCT04349436)
- Testing
- RP1, intra-tumoral injection, oncolytic virus
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Replimune, Inc.
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors
This is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy or with sintilimab in…
- Trial name
- NCT05718219
- Testing
- SIM0348, SIM0348 + Sintilimab
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Neoplasms
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
- Trial name
- NCT00528619
- Testing
- Sunitinib, Pemetrexed, Cisplatin, Carboplatin
- Where
- 3 sites in United States, Canada
- Volunteers
- 96 people
- Sponsor
- Pfizer
Solid Tumors
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
The purpose of this study is to determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among participants with advanced solid tumors refractory to standard treatment or for which no standard…
- Trial name
- NCT01624467
- Testing
- Necitumumab
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.